Syndax Pharmaceuticals (SNDX) Non Operating Income (2015 - 2026)

Syndax Pharmaceuticals' Non Operating Income history runs 12 years deep, the most recent figure standing at -$8.5 million for Q1 2026.

• On a quarterly basis, Non Operating Income fell 677.87% year-over-year to -$8.5 million in Q1 2026; TTM through Mar 2026 was -$19.7 million, a 255.14% decrease from a year earlier, with the FY2025 full-year figure at -$12.3 million, down 158.99% from the prior year.
• Non Operating Income eased to -$8.5 million in Q1 2026 per SNDX's latest filing, from -$5.5 million in the prior quarter.
• Across five years, Non Operating Income topped out at $7.1 million in Q1 2024 and bottomed at -$8.5 million in Q1 2026.
• The 5-year median for Non Operating Income is $2.2 million (2024), against an average of $1.4 million.
• Across the five-year window, Non Operating Income soared 3230.92% in 2023 and slumped 677.87% in 2026, its largest moves.
• Year by year, Non Operating Income stood at $2.8 million in 2022, then jumped by 91.33% to $5.4 million in 2023, then plunged by 59.57% to $2.2 million in 2024, then tumbled by 348.91% to -$5.5 million in 2025, then slumped by 54.98% to -$8.5 million in 2026.
• Per Business Quant, the three latest SNDX Non Operating Income figures stand at -$8.5 million (Q1 2026), -$5.5 million (Q4 2025), and -$3.3 million (Q3 2025).